GO:0001576 globoside biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001576 (globoside biosynthetic process) describes the enzymatic assembly of globo-series glycosphingolipids, beginning with the tetrasaccharide core GalNAc-beta-1,3-Gal-alpha-1,4-Gal-beta-1,4-Glc-ceramide.
• Globoside (Gb4) and related globo-series glycans are built by sequential glycosyltransferase reactions and can be further elongated or modified.
• Globoside is a critical host factor for parvovirus B19 entry and endosomal escape, making this pathway directly relevant to infectious disease research.
• Altered globoside-series glycosphingolipid abundance has been reported in hepatocellular carcinoma, linking the pathway to cancer biology.
• Shiga toxins exploit globo-series glycosphingolipids as receptors, connecting this biosynthetic process to bacterial toxin pathology.
• CRISPR knockout, knock-in, and overexpression models enable causal testing of glycosyltransferase genes in globoside biosynthesis.
Description
Globoside biosynthetic process (GO:0001576) is the biological process that produces globosides, a class of neutral glycosphingolipids defined by a GalNAc-beta-1,3-Gal-alpha-1,4-Gal-beta-1,4-Glc-ceramide tetrasaccharide core. This core, often called globotetraosylceramide or Gb4, serves as a scaffold that can be further elongated with additional carbohydrate units, generating a family of globo-series glycosphingolipids with diverse biological roles. The pathway is initiated in the endoplasmic reticulum and completed in the Golgi apparatus through the sequential action of glycosyltransferases, and its products are embedded in the plasma membrane and other cellular membranes. Researchers study GO:0001576 because globoside and its derivatives are not merely structural lipids; they function as receptors, antigens, and signaling molecules. For example, globoside is an essential intracellular factor for parvovirus B19 endosomal escape, and the mucosal pH can modulate B19 entry through the epithelial barrier. In cancer, changes in glycosphingolipid abundance, including globo-series species, have been documented in hepatocellular carcinoma. Moreover, Shiga toxins bind globo-series glycosphingolipids, linking this pathway to bacterial pathogenesis. Understanding the enzymes and regulation of globoside biosynthesis therefore has implications for infectious disease, oncology, and immunology. This article provides a research-grade overview of GO:0001576, covering its definition, enzymatic steps, key genes, disease connections, and experimental methods. All statements are grounded in published literature and the QuickGO definition, with citations to verified PubMed records.
globoside biosynthetic process At A Glance
| GO ID | GO:0001576 |
|---|---|
| GO term | globoside biosynthetic process |
| Ontology | biological_process |
| Synonym | globo-series glycosphingolipid biosynthesis; globoside anabolism; globoside biosynthesis; globoside formation; globoside synthesis |
| Major function | Synthesis of globoside (Gb4) and related globo-series glycosphingolipids from a GalNAc-beta-1,3-Gal-alpha-1,4-Gal-beta-1,4-Glc-ceramide core |
| Subcellular location | Endoplasmic reticulum and Golgi apparatus (glycosyltransferase reactions) |
| Key enzymes | Glycosyltransferases including B3GALNT1, A4GALT, B3GALT1/2, and others |
| Pathway context | Glycosphingolipid metabolism; globo-series biosynthesis |
| Disease relevance | Parvovirus B19 infection, hepatocellular carcinoma, Shiga toxin pathology, Sandhoff disease (related glycosphingolipid storage) |
What Is GO:0001576?
According to the Gene Ontology, globoside biosynthetic process (GO:0001576) is defined as the chemical reactions and pathways resulting in the formation of globosides that begins with the synthesis of a tetrasaccharide core GalNAc-beta-1,3-Gal-alpha-1,4-Gal-beta-1,4-Glc-ceramide. This core can be further elongated with the sequential addition of various carbohydrate units. In simpler terms, it is the set of enzymatic steps that build globo-series glycosphingolipids starting from a specific four-sugar lipid anchor and then extend it with more sugars.
Why Is globoside biosynthetic process Important in Cell Biology?
Globoside biosynthetic process is important because its products are key cell-surface molecules that mediate host-pathogen interactions, immune recognition, and cancer-associated glycosylation changes. Globoside itself is the primary receptor for parvovirus B19 and is required for endosomal escape of the virus, making the pathway a determinant of viral tropism and pathogenesis. In cancer, altered globo-series glycosphingolipid abundance has been observed in hepatocellular carcinoma, suggesting roles in tumor biology. Additionally, Shiga toxins bind globo-series glycosphingolipids, linking the pathway to bacterial toxin entry and disease. Understanding this pathway provides insights into infectious disease, oncology, and glycolipid storage disorders.
• Globoside is an essential host factor for parvovirus B19 entry and endosomal escape.
• The pathway determines susceptibility to parvovirus B19 in human placenta.
• Altered globoside-series glycosphingolipid levels are associated with hepatocellular carcinoma.
• Shiga toxins use globo-series glycosphingolipids as receptors, contributing to bacterial pathogenesis.
• Glycosphingolipids, including globosides, are immunogenic and can elicit immune responses.
• Defects in glycosphingolipid catabolism, as in Sandhoff disease, highlight the importance of balanced synthesis and degradation.
• Globoside biosynthesis enzymes are potential targets for antiviral and anticancer strategies.
• The pathway is a model for studying sequential glycosyltransferase reactions in the Golgi.
• CRISPR screens can identify genes required for globoside biosynthesis and viral entry.
• Understanding globoside biosynthesis aids in interpreting glycosphingolipid profiles in disease.
What Happens During globoside biosynthetic process?
Initiation: Synthesis of the tetrasaccharide core
In simple terms: The cell starts building globoside by attaching four specific sugars to a lipid carrier.
The globoside biosynthetic process begins with the synthesis of the tetrasaccharide core GalNAc-beta-1,3-Gal-alpha-1,4-Gal-beta-1,4-Glc-ceramide. This core is assembled by sequential glycosyltransferase reactions in the endoplasmic reticulum and Golgi apparatus. The first steps involve the addition of glucose and galactose to ceramide, followed by the addition of a second galactose in an alpha linkage and then a GalNAc residue in a beta-1,3 linkage. The resulting Gb4 (globoside) is the defining product of this stage.
Elongation and diversification
In simple terms: After the core is made, more sugars can be added to create different globo-series molecules.
The tetrasaccharide core can be further elongated with the sequential addition of various carbohydrate units, generating a diverse family of globo-series glycosphingolipids. These elongation reactions are catalyzed by additional glycosyltransferases and can produce antigens such as the P blood group antigens. The specific elongation pattern depends on the expression of enzymes and the availability of nucleotide sugar donors.
Subcellular organization
In simple terms: The building process happens in specific compartments of the cell, mainly the ER and Golgi.
Globoside biosynthesis is spatially organized: the initial steps occur in the endoplasmic reticulum, and later steps, including the addition of the terminal GalNAc, take place in the Golgi apparatus. This compartmentalization ensures that enzymes and substrates meet in the correct order. The final globoside products are then transported to the plasma membrane and other membranes.
Role in host-pathogen interactions
In simple terms: Once made, globoside can act as a door for certain viruses and toxins.
Globoside on the cell surface serves as a receptor for parvovirus B19 and Shiga toxins. For parvovirus B19, globoside is required for endosomal escape, and the mucosal pH can modulate entry through the epithelial barrier. This highlights how the biosynthetic process directly impacts susceptibility to infection. The presence of globoside in the placenta also influences B19 susceptibility.
Regulation of flux through the pathway
In simple terms: The cell can adjust how much globoside it makes by changing enzyme levels or activity.
The flux through globoside biosynthesis can be regulated at the level of glycosyltransferase gene expression, enzyme activity, and substrate availability. While specific transcriptional regulators of this pathway are not fully defined in the provided literature, changes in globo-series glycosphingolipid abundance in hepatocellular carcinoma suggest that the pathway is subject to disease-associated regulation. Additionally, the immunogenicity of glycolipids indicates that immune mechanisms may influence globoside turnover.
Key Genes Involved in GO:0001576 globoside biosynthetic process
The following genes encode enzymes and related proteins involved in globoside biosynthetic process and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| A4GALT | Alpha-1,4-galactosyltransferase; adds galactose to lactosylceramide to form Gb3 | Key enzyme in globo-series biosynthesis; mutations affect P blood group antigens |
| B3GALNT1 | Beta-1,3-N-acetylgalactosaminyltransferase; adds GalNAc to Gb3 to form Gb4 (globoside) | Directly responsible for the defining step of globoside biosynthesis |
| B3GALT1 | Beta-1,3-galactosyltransferase; may elongate globo-series glycans | Potential modifier of globoside elongation |
| B3GALT2 | Beta-1,3-galactosyltransferase; involved in glycosphingolipid synthesis | May contribute to globo-series diversity |
| UGCG | UDP-glucose ceramide glucosyltransferase; first step in glycosphingolipid synthesis | Upstream of globoside biosynthesis; knockout abolishes globosides |
| B4GALT5 | Beta-1,4-galactosyltransferase; synthesizes lactosylceramide | Provides substrate for globo-series pathway |
| B4GALT6 | Beta-1,4-galactosyltransferase; synthesizes lactosylceramide | Redundant with B4GALT5 in some tissues |
| GLA | Alpha-galactosidase A; degrades globotriaosylceramide | Deficiency causes Fabry disease; related to globo-series catabolism |
| HEXA | Beta-hexosaminidase A; degrades GM2 ganglioside and globoside | Deficiency causes Tay-Sachs and Sandhoff disease |
| HEXB | Beta-hexosaminidase B; degrades globoside and other glycosphingolipids | Deficiency causes Sandhoff disease |
| GM2A | GM2 ganglioside activator; assists in glycosphingolipid degradation | Deficiency causes GM2 gangliosidosis |
| B4GALNT1 | Beta-1,4-N-acetylgalactosaminyltransferase; synthesizes GM2/GD2 | Not directly in globo-series but related glycosphingolipid pathway |
| ST3GAL5 | Sialyltransferase; synthesizes gangliosides | Competes with globo-series for lactosylceramide |
| FUT1 | Fucosyltransferase; synthesizes blood group antigens | May modify globo-series glycans |
| FUT2 | Fucosyltransferase; synthesizes blood group antigens | May modify globo-series glycans |
| ABO | Glycosyltransferase; synthesizes A/B blood group antigens | May compete for common substrates |
| B3GNT5 | Beta-1,3-N-acetylglucosaminyltransferase; elongates lacto/neolacto series | Competes with globo-series for lactosylceramide |
| CERK | Ceramide kinase; regulates ceramide levels | Indirectly affects glycosphingolipid synthesis |
How Is globoside biosynthetic process Regulated?
The regulation of globoside biosynthetic process is not fully characterized in the provided literature, but general principles of glycosphingolipid metabolism apply. The pathway is controlled by the expression and activity of glycosyltransferases, availability of nucleotide sugar donors, and ceramide levels. Disease-associated changes, such as altered globo-series glycosphingolipid abundance in hepatocellular carcinoma, suggest that the pathway is subject to regulation in pathological states. Additionally, immune mechanisms may influence glycolipid turnover due to their immunogenicity. Further research is needed to define specific transcriptional or signaling regulators of this pathway.
globoside biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| B3GALNT1 | Parvovirus B19 susceptibility; globoside deficiency | Knockout in HeLa or UT7/Epo cells; viral entry assay |
| A4GALT | P blood group phenotype; Shiga toxin susceptibility | Knockout in HeLa cells; toxin binding assay |
| HEXB | Sandhoff disease; globoside accumulation | Knockout in patient fibroblasts; lipidomics |
| B3GALT1 | Cancer-associated glycosylation changes | Overexpression in hepatocellular carcinoma cell lines |
| UGCG | Glycosphingolipid depletion; viral resistance | Knockout in HEK293T; parvovirus B19 infection |
Parvovirus B19 infection
Globoside is an essential host factor for parvovirus B19. The virus uses globoside for endosomal escape, and the mucosal pH mediates B19 entry through the epithelial barrier. Cellular determinants of B19 susceptibility in the human placenta also involve globoside. Therefore, the globoside biosynthetic process directly influences viral tropism and pathogenesis.
Hepatocellular carcinoma
Alterations in glycosphingolipid abundance, including globo-series species, have been reported in hepatocellular carcinoma. This suggests that globoside biosynthesis may contribute to cancer-associated glycosylation changes, although the exact mechanisms remain to be elucidated.
Shiga toxin pathology
Shiga toxins bind globo-series glycosphingolipids, particularly globotriaosylceramide (Gb3), to enter cells. The globoside biosynthetic process provides the receptors for these toxins, linking the pathway to bacterial pathogenesis and hemolytic uremic syndrome.
Sandhoff disease and related storage disorders
Sandhoff disease is a lysosomal storage disorder caused by deficiency of beta-hexosaminidase, leading to accumulation of glycosphingolipids including globoside. This highlights the importance of balanced synthesis and degradation of globosides. While the biosynthetic process itself is not the primary defect, its products accumulate when degradation is impaired.
From globoside biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does B3GALNT1 knockout abolish globoside biosynthesis? | CRISPR knockout in HeLa or HEK293T cells |
| Does a point mutation in A4GALT alter globoside levels? | CRISPR point mutation knock-in in K562 cells |
| Can globoside biosynthesis be restored by knock-in of wild-type B3GALNT1? | Knock-in of B3GALNT1 cDNA into knockout background |
| Where is B3GALNT1 localized in the Golgi? | Tagged knock-in with GFP or FLAG |
| Does overexpression of A4GALT increase globoside and enhance viral entry? | Overexpression in epithelial cell lines |
| Which genes are essential for globoside biosynthesis? | Genome-wide CRISPR library screening in cells with globoside-dependent infection |
How to Study the globoside biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Gene function | Test if B3GALNT1 is required for globoside synthesis |
| CRISPR point mutation | Specific amino acid function | Assess catalytic residues in A4GALT |
| Knock-in | Protein localization or rescue | Tag B3GALNT1 with GFP to study Golgi localization |
| Overexpression | Gain-of-function | Increase globoside levels to study viral entry |
| Lipidomics (LC-MS) | Glycosphingolipid abundance | Quantify globoside in cancer cells |
| Flow cytometry | Cell-surface globoside | Measure globoside after gene editing |
| CRISPR library screening | Genome-wide essential genes | Identify novel regulators of globoside biosynthesis |
CRISPR knockout and viral entry assays
CRISPR knockout of glycosyltransferase genes such as B3GALNT1 or A4GALT followed by parvovirus B19 infection can test whether globoside biosynthesis is required for viral entry and endosomal escape. These assays typically use HeLa or UT7/Epo cells and measure viral replication or reporter expression.
Lipidomics and mass spectrometry
Mass spectrometry-based lipidomics can quantify globoside and related glycosphingolipids in cells and tissues. This approach has been used to profile glycosphingolipid abundance in hepatocellular carcinoma and can validate changes after genetic manipulation.
Flow cytometry and antibody-based detection
Flow cytometry with anti-globoside antibodies or Shiga toxin binding can measure cell-surface globoside levels. This method is useful for screening knockout clones and assessing the impact of point mutations on globoside presentation.
CRISPR library screening
Genome-wide CRISPR knockout libraries can identify genes required for globoside biosynthesis and viral entry. Cells are infected with a globoside-dependent virus, and resistant clones are sequenced to identify enriched sgRNAs targeting glycosyltransferase genes.
How CRISPR Can Be Used to Study GO:0001576 globoside biosynthetic process
Knockout
CRISPR knockout of B3GALNT1 or A4GALT can completely abolish globoside biosynthesis, providing a clean background to study its functions. Such knockouts have been used to demonstrate the requirement for globoside in parvovirus B19 endosomal escape. Knockout cell lines are also valuable for lipidomics and toxin binding studies.
Point Mutation
CRISPR point mutation can introduce specific amino acid substitutions in glycosyltransferases to dissect catalytic mechanisms. For example, mutating the catalytic base of B3GALNT1 can distinguish enzyme activity from structural roles. Point mutations can also model human polymorphisms affecting globoside levels.
Knock-in
Knock-in of tagged versions of B3GALNT1 or A4GALT (e.g., GFP or FLAG) allows visualization of enzyme localization and trafficking in the Golgi. Knock-in of wild-type cDNA into a knockout background can rescue globoside biosynthesis and confirm specificity. This approach is useful for studying protein-protein interactions.
Overexpression
Overexpression of A4GALT or B3GALNT1 can increase globoside levels and enhance viral entry or toxin sensitivity. This gain-of-function approach helps establish sufficiency of individual enzymes in the pathway. Overexpression models are also used to study cancer-associated glycosylation changes.
How EDITGENE Supports globoside biosynthetic process Research
Researchers studying globoside biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in the pathway, how specific mutations affect enzyme function, and where the encoded protein localizes. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for globoside biosynthetic process research.
Frequently Asked Questions About globoside biosynthetic process
What is globoside biosynthetic process?
Globoside biosynthetic process (GO:0001576) is the set of enzymatic reactions that produce globosides, starting with the synthesis of a GalNAc-beta-1,3-Gal-alpha-1,4-Gal-beta-1,4-Glc-ceramide core, which can be further elongated.
What genes are involved in globoside biosynthetic process?
Key genes include A4GALT, B3GALNT1, UGCG, and B4GALT5/6, which encode glycosyltransferases that sequentially build the globoside core.
Why is globoside important for parvovirus B19?
Globoside is an essential host factor for parvovirus B19 endosomal escape, and the mucosal pH mediates B19 entry through the epithelial barrier.
Is globoside involved in cancer?
Altered globo-series glycosphingolipid abundance has been reported in hepatocellular carcinoma, suggesting a role in cancer biology.
What diseases are associated with globoside biosynthesis?
Globoside biosynthesis is linked to parvovirus B19 infection, Shiga toxin pathology, and Sandhoff disease through glycosphingolipid accumulation.
How can I study globoside biosynthesis using CRISPR?
CRISPR knockout of B3GALNT1 or A4GALT abolishes globoside production, and knock-in or overexpression can restore or increase it. These models are used with lipidomics and viral entry assays.
What is the role of B3GALNT1 in globoside biosynthesis?
B3GALNT1 adds the terminal GalNAc to Gb3 to form globoside (Gb4), the defining step of the pathway.
What are globo-series glycosphingolipids?
Globo-series glycosphingolipids are a family of neutral glycosphingolipids built on a GalNAc-beta-1,3-Gal-alpha-1,4-Gal-beta-1,4-Glc-ceramide core, including globoside and its elongated derivatives.
How does Shiga toxin interact with globoside?
Shiga toxins bind globo-series glycosphingolipids, particularly Gb3, to enter cells, linking the pathway to bacterial pathogenesis.
What methods are used to measure globoside levels?
Mass spectrometry lipidomics, flow cytometry with anti-globoside antibodies, and Shiga toxin binding assays are commonly used to measure globoside levels.
Conclusion
Globoside biosynthetic process (GO:0001576) is a fundamental glycosphingolipid pathway that produces globoside and related globo-series molecules. Its products are critical for host-pathogen interactions, including parvovirus B19 entry and Shiga toxin binding, and are altered in cancer. Understanding the enzymes and regulation of this pathway offers opportunities for therapeutic intervention and biomarker development. CRISPR-based models provide powerful tools to dissect the pathway and its disease relevance.
References
- 1. Portoukalian J. 2000. Immunogenicity of glycolipids.. Clin Rev Allergy Immunol 19(1):73-8 PMID: 11064828
- 2. Suter C et al.. 2023. Globoside and the mucosal pH mediate parvovirus B19 entry through the epithelial barrier.. PLoS Pathog 19(5):e1011402 PMID: 37220143
- 3. Byrne FL et al.. 2022. Update on Glycosphingolipids Abundance in Hepatocellular Carcinoma.. Int J Mol Sci 23(9) PMID: 35562868
- 5. Bieri J et al.. 2024. Globoside Is an Essential Intracellular Factor Required for Parvovirus B19 Endosomal Escape.. Cells 13(15) PMID: 39120285
- 6. Tatematsu M et al.. 1981. Sandhoff disease.. Acta Pathol Jpn 31(3):503-12 PMID: 7270152
- 7. Suter C et al.. 2026. Cellular determinants of parvovirus B19 susceptibility in the human placenta.. PLoS Pathog 22(2):e1013984 PMID: 41706746
- 8. Chan YS et al.. 2016. Shiga toxins: from structure and mechanism to applications.. Appl Microbiol Biotechnol 100(4):1597-1610 PMID: 26685676
